ReviewJournal of ophthalmic inflammation and infection2026
Rosacea scleritis and sclero-uveitis; under recognised and over treated.
Review in Journal of ophthalmic inflammation and infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRosacea episcleritis, scleritis and uveitis may be missed when clinicians focus on the eye without appraising the adnexae and facial skin. Addressing rosacea can reduce treatment failures and avoid systemic complications of less effective or more toxic drugs. CASE SERIES AND NARRATIVE REVIEW: This series presents four cases with scleritis and / or sclero-uveitis in the setting of facial or ocular rosacea. Where relevant, negative systemic scleritis work up is included. Common features were incomplete resolution or poor response to one or more of topical and systemic steroid, systemic non-steroidal anti-inflammatory, systemic immunomodulatory and topical antibiotic treatment. All cases responded promptly to treatment with oral doxycycline, allowing withdrawal of other treatment. A review of the literature is presented, updating understanding of immunogenetics and inflammatory pathways relevant to ophthalmic management of these cases. Important considerations include the role of steroids, vitamin D, microbes, toll like receptors and their influence on the cathelicidin (Ll-17) pathway in rosacea inflammation.
conclusionMaking a correct rosacea diagnosis and managing with doxycycline or related medication can result in rapid remission, minimising disease complications and side effects of less targeted drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.